01498nas a2200277   4500000000100000008004100001260000900042653002000051653003000071653002100101653001100122653002300133653001200156653001900168653001900187653001500206653001700221100002000238700001200258700001400270245019000284300001100474490000600485520071500491022001401206       1995                            d  c199510aAfrica, Western10aDrug Therapy, Combination10aHealth Promotion10aHumans10aLeprostatic Agents10aleprosy10aMass Screening10aPilot Projects10aPrevalence10aRisk Factors1 aTiendrebéogo A1 aBlanc L1 aSylla P M00a[Antileprosy polychemotherapy in the member states of the OCCGE: a decade of implementation (1983-19930). The National Coordinators of the Leprosy Program of the 8 states of the OCCGE].  a139-470 v93 a<p>MDT for leprosy recommended by WHO in 1981 has been introduced and implemented in 8 Member States of OCCGE (an organization for leprosy control in francophone West Africa). This implementation from 1983 to 1993 can be divided in two phases: 1983-1987: introduction phase by pilot projects; 1988-1993: extension phase by national leprosy control programmes. During the ten years, MDT coverage rose to 68%, leprosy prevalence rate widely decreased (40.71 to 6.56 per 10,000), while annual detection rate weakly varied (1.89 to 1.26 per 10,000). Factors influencing this evolution of leprosy are brought out and recommendations are made about strategies to be developed for leprosy control up to year 2000.</p>  a0001-5938